The rationale behind the quest for additional genetic events grows out of the heterogeneity of clinical outcomes and GIST patients' treatment responses, which suggests that molecular events other than gain-of-function mutations in KIT and PDGFRα are involved in the biological behavior of tumor aggressiveness. The gene discussed is KIT; the disease is neoplasm.